Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 22
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Mycoses ; 67(3): e13704, 2024 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-38429226

RESUMEN

BACKGROUND: Meyerozyma guilliermondii is a yeast species responsible for invasive fungal infections. It has high minimum inhibitory concentrations (MICs) to echinocandins, the first-line treatment of candidemia. In this context, azole antifungal agents are frequently used. However, in recent years, a number of azole-resistant strains have been described. Their mechanisms of resistance are currently poorly studied. OBJECTIVE: The aim of this study was consequently to understand the mechanisms of azole resistance in several clinical isolates of M. guilliermondii. METHODS: Ten isolates of M. guilliermondii and the ATCC 6260 reference strain were studied. MICs of azoles were determined first. Whole genome sequencing of the isolates was then carried out and the mutations identified in ERG11 were expressed in a CTG clade yeast model (C. lusitaniae). RNA expression of ERG11, MDR1 and CDR1 was evaluated by quantitative PCR. A phylogenic analysis was developed and performed on M. guilliermondii isolates. Lastly, in vitro experiments on fitness cost and virulence were carried out. RESULTS: Of the ten isolates tested, three showed pan-azole resistance. A combination of F126L and L505F mutations in Erg11 was highlighted in these three isolates. Interestingly, a combination of these two mutations was necessary to confer azole resistance. An overexpression of the Cdr1 efflux pump was also evidenced in one strain. Moreover, the three pan-azole-resistant isolates were shown to be genetically related and not associated with a fitness cost or a lower virulence, suggesting a possible clonal transmission. CONCLUSION: In conclusion, this study identified an original combination of ERG11 mutations responsible for pan-azole-resistance in M. guilliermondii. Moreover, we proposed a new MLST analysis for M. guilliermondii that identified possible clonal transmission of pan-azole-resistant strains. Future studies are needed to investigate the distribution of this clone in hospital environment and should lead to the reconsideration of the treatment for this species.


Asunto(s)
Azoles , Farmacorresistencia Fúngica , Saccharomycetales , Humanos , Azoles/farmacología , Tipificación de Secuencias Multilocus , Farmacorresistencia Fúngica/genética , Antifúngicos/farmacología , Mutación , Pruebas de Sensibilidad Microbiana , Fluconazol/farmacología
2.
Mycoses ; 67(1): e13676, 2024 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-37984556

RESUMEN

BACKGROUND: Data on the risk of invasive fungal infections (IFI) with ibrutinib treatment are scarce. OBJECTIVES: This study aimed to determine IFI incidence and risk factors in ibrutinib-treated patients in real-life settings. METHODS: We constituted a cohort of ibrutinib incident users in the French National Healthcare Database. All patients ≥18 years with a first dispensing of ibrutinib between 21 November 2014 and 31 December 2019 were included. Patients were followed from the cohort entry date until IFI, ibrutinib discontinuation, death, or 31 December 2020, whichever came first. The cumulative incidence function method was used to estimate the probability of IFI accounting for competing risk of death. A multivariate cause-specific Cox proportional hazards model was used to assess independent IFI risk factors. RESULTS: Among 6937 ibrutinib-treated patients, 1-year IFI cumulative incidence was 1.3%, with invasive aspergillosis being the most frequent. Allogenic or autologous stem cell transplantation (ASCT) (hazard ratio [HR] 3.59, 95% confidence interval [1.74; 7.41]), previous anticancer treatment (HR 2.12, CI 95% [1.34; 3.35]) and chronic respiratory disease (HR 1.66, [1.03; 2.67]) were associated with higher risk of IFI. Besides neutropenia and corticosteroids, use of anti-CD20 agents was significantly more frequent in patients having experienced IFI (HR 3.68, [1.82; 7.45]). CONCLUSIONS: In addition to patients with ASCT history, severe neutropenia or treated with corticosteroids, our findings support active surveillance of IFIs in those with chronic respiratory disease, previously treated, or treated with anti-CD20 agents in combination with ibrutinib. Further studies are needed to optimise IFI prophylaxis in these patient subgroups.


Asunto(s)
Adenina/análogos & derivados , Trasplante de Células Madre Hematopoyéticas , Infecciones Fúngicas Invasoras , Neutropenia , Piperidinas , Humanos , Incidencia , Estudios de Cohortes , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Trasplante Autólogo/efectos adversos , Infecciones Fúngicas Invasoras/tratamiento farmacológico , Infecciones Fúngicas Invasoras/epidemiología , Infecciones Fúngicas Invasoras/etiología , Factores de Riesgo , Neutropenia/complicaciones , Corticoesteroides/uso terapéutico , Antifúngicos/uso terapéutico , Estudios Retrospectivos
3.
Mycopathologia ; 188(3): 255-257, 2023 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-37022620

RESUMEN

Rhinocladiella similis is a melanized fungi involved in chromoblastomycosis. R. similis genome has never been sequenced, therefore we propose the first draft genome of R. similis.


Asunto(s)
Ascomicetos , Cromoblastomicosis , Ascomicetos/genética , Cromoblastomicosis/microbiología
4.
Mycopathologia ; 187(4): 413-415, 2022 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-35829847

RESUMEN

Kazachstania bovina is a yeast species from the K. telluris complex that has been recently involved in bloodstream infections. While yeast genomes from this complex have already been sequenced, K. bovina genome has not been published yet. Here is the first draft genome of K. bovina (CBS 16326).


Asunto(s)
ADN de Hongos , ADN de Hongos/genética , Humanos , Técnicas de Tipificación Micológica , Filogenia , Saccharomycetales , Análisis de Secuencia de ADN
5.
Can J Microbiol ; 68(6): 427-434, 2022 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-35286812

RESUMEN

Few antifungal agents are currently available for the treatment of fungal infections. Antimicrobial peptides (AMPs), which are natural molecules involved in the innate immune response of many organisms, represent a promising research method because of their broad killing activity. The aim of this study was to assess the activity of a frog AMP, [K3]temporin-SHa, against some species of yeasts and moulds, and to further explore its activity against Candida albicans. MIC determinations were performed according to EUCAST guidelines. Next, the activity of [K3]temporin-SHa against C. albicans was explored using time-killing curve experiments, membrane permeabilization assays, and electron microscopy. Finally, chequerboard assays were performed to evaluate the synergy between [K3]temporin-SHa and amphotericin B or fluconazole. [K3]temporin-SHa was found to be active in vitro against several yeasts with MIC between 5.5 and 45 µM. [K3]temporin-SHa displayed rapid fungicidal activity against C. albicans (inoculum was divided into two in less than an hour and no viable colonies were recovered after 5 h) with a mechanism that could be due to membrane permeabilization. [K3]temporin-SHa was synergistic with amphotericin B against C. albicans (FICI = 0.303). [K3]temporin-SHa could represent an additional tool to treat several Candida species and C. neoformans.


Asunto(s)
Anfotericina B , Antifúngicos , Anfotericina B/farmacología , Antifúngicos/farmacología , Péptidos Catiónicos Antimicrobianos/farmacología , Candida albicans , Fluconazol/farmacología , Pruebas de Sensibilidad Microbiana , Levaduras
6.
Pharmaceutics ; 14(3)2022 Mar 14.
Artículo en Inglés | MEDLINE | ID: mdl-35336015

RESUMEN

Pulmonary mold infections are life-threatening diseases with high morbi-mortalities. Treatment is based on systemic antifungal agents belonging to the families of polyenes (amphotericin B) and triazoles. Despite this treatment, mortality remains high and the doses of systemic antifungals cannot be increased as they often lead to toxicity. The pulmonary aerosolization of antifungal agents can theoretically increase their concentration at the infectious site, which could improve their efficacy while limiting their systemic exposure and toxicity. However, clinical experience is poor and thus inhaled agent utilization remains unclear in term of indications, drugs, and devices. This comprehensive literature review aims to describe the pharmacokinetic behavior and the efficacy of inhaled antifungal drugs as prophylaxes and curative treatments both in animal models and humans.

7.
J Fungi (Basel) ; 8(2)2022 Jan 27.
Artículo en Inglés | MEDLINE | ID: mdl-35205875

RESUMEN

The aim of this study was to evaluate the effect of the combination of amphotericin B (AmB) and various non-ionic surfactants on the anti-Mucorales activity of AmB, the toxicity of the combination on eukaryotic cells and the modification of AmB aggregation states. Checkerboards were performed on five genera of Mucorales (12 strains) using several combinations of different surfactants and AmB. These data were analyzed by an Emax model. The effect of surfactants on the cytotoxic activity of AmB was then evaluated for red blood cells and two eukaryotic cell lines by absorbance and propidium iodide internalization. Finally, the effect of polyethylene glycol (15)-hydroxystearate (PEG15HS) on the aggregation states of AmB was evaluated by UV-visible spectrometry. PEG15HS increased the efficacy of AmB on four of the five Mucorales genera, and MICs of AmB were decreased up to 68-fold for L. ramosa. PEG15HS was the only surfactant to not increase the cytotoxic activity of AmB. Finally, the analysis of AmB aggregation states showed that the increased efficacy of AmB and the absence of toxicity are related to an increase in monomeric and polyaggregated forms of AmB at the detriment of the dimeric form. In conclusion, PEG15HS increases the in vitro efficacy of AmB against Mucorales at low concentration, without increasing its toxicity; this combination could therefore be evaluated in the treatment of mucormycosis.

8.
J Clin Immunol ; 42(1): 60-63, 2022 01.
Artículo en Inglés | MEDLINE | ID: mdl-34596815

RESUMEN

Chronic granulomatous disease (CGD) is an inherited immunodeficiency due to defective leukocyte NADPH responsible for recurrent infections and aberrant inflammation. Mutations in the CYBB gene are responsible for the X-linked CGD and account for approximately 70% of the cases. CGD is diagnosed during childhood in males. Female carriers may have biased X-inactivation and may present with clinical manifestations depending on the level of residual NADPH oxidase activity. We report the case of a previously asymptomatic female carrier who was diagnosed at age 67 with a skin infection with the rare fungus Paecilomyces lilacinus as the first manifestation of CGD. Dihydrorhodamine 123 (DHR) activity was below 10%. Next-generation sequencing (NGS) revealed mutations in DNMT3A, ASXL1, and STAG2 suggesting that clonal hematopoiesis could be responsible for a progressive loss of NADPH oxidase activity and the late onset of X-linked CGD in this patient. Long-term follow-up of asymptomatic carrier women seems to be essential after 50 years old.


Asunto(s)
Enfermedad Granulomatosa Crónica , Hypocreales , Anciano , Enfermedad Granulomatosa Crónica/diagnóstico , Enfermedad Granulomatosa Crónica/genética , Humanos , Persona de Mediana Edad , NADPH Oxidasas/genética , Inactivación del Cromosoma X
9.
Med Mycol ; 59(7): 694-700, 2021 Jul 06.
Artículo en Inglés | MEDLINE | ID: mdl-33369666

RESUMEN

Alveolar macrophages (AM) are the first-line lung defense against Mucorales in pulmonary mucormycosis. Since corticosteroid use is a known risk factor for mucormycosis, the aim of this study was to describe the role of corticosteroids on AM capacities to control Lichtheimia corymbifera spore growth using a new ex vivo model. An in vivo mouse model was developed to determine the acetate cortisone dose able to trigger pulmonary invasive infection. Then, in the ex vivo model, male BALB/c mice were pretreated with the corticosteroid regimen triggering invasive infection, before AM collection through bronchoalveolar lavage. AMs from corticosteroid-treated mice and untreated control AMs were then exposed to L. corymbifera spores in vitro (ratio 1:5). AM control of fungal growth, adherence/phagocytosis, and oxidative burst were assessed using optical densities by spectrophotometer, flow cytometry, and 2', 7'-dichlorofluoresceine diacetate fluorescence, respectively. Cortisone acetate at 500 mg/kg, at D-3 and at D0, led to pulmonary invasive infection at D3. Co-incubated spores and AMs from corticosteroid-treated mice had significantly higher absorbance (fungal growth) than co-incubated spores and control AMs, at 24 h (P = .025), 36 h (P = .004), and 48 h (P = .001). Colocalization of spores with AMs from corticosteroid-treated mice was significantly lower than for control AMs (7.6 ± 1.9% vs 22.3 ± 5.8%; P = .003), reflecting spore adherence and phagocytosis inhibition. Finally, oxidative burst was significantly increased when control AMs were incubated with spores (P = 0.029), while corticosteroids hampered oxidative burst from treated AMs (P = 0.321). Corticosteroids enhanced fungal growth of L. corymbifera through AM phagocytosis inhibition and burst oxidative decrease in our ex vivo model. LAY SUMMARY: The aim of this study was to describe the impact of corticosteroids on alveolar macrophage (AM) capacities to control Mucorales growth in a new murine ex vivo model. Corticosteroids enhanced fungal growth of L. corymbifera through AM phagocytosis inhibition and burst oxidative decrease.


Asunto(s)
Corticoesteroides/administración & dosificación , Pulmón/microbiología , Macrófagos Alveolares/efectos de los fármacos , Mucorales/efectos de los fármacos , Fagocitosis/efectos de los fármacos , Esporas Fúngicas/efectos de los fármacos , Animales , Modelos Animales de Enfermedad , Humanos , Pulmón/efectos de los fármacos , Macrófagos Alveolares/microbiología , Masculino , Ratones , Ratones Endogámicos BALB C , Mucorales/crecimiento & desarrollo , Mucormicosis/inmunología , Mucormicosis/microbiología
12.
IDCases ; 20: e00777, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32518751

RESUMEN

A female 66 year-old patient, not immunocompromised, was admitted in ICU for severe influenza complicated by severe acute respiratory distress syndrome (ARDS) leading to extra-corporeal membrane oxygenation (ECMO). During ICU hospitalization, she developed a disseminated invasive aspergillosis with cerebral access and coronary occlusion which lead to cardiac arrest. Despite a successful revascularization procedure, the patient died of refractory shock.

13.
Emerg Infect Dis ; 26(3): 626-627, 2020 03.
Artículo en Inglés | MEDLINE | ID: mdl-32091374

RESUMEN

New Candida species such as Candida auris have emerged recently as important invasive fungal diseases. We report a case of C. bovina bloodstream infection in a 94-year-old patient in France. The species led to identification issues because it was misidentified by phenotypic and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry methods.


Asunto(s)
Candidiasis Invasiva/diagnóstico , Saccharomycetales/aislamiento & purificación , Anciano de 80 o más Años , Antifúngicos/farmacología , Antifúngicos/uso terapéutico , Candidiasis Invasiva/tratamiento farmacológico , Diagnóstico Diferencial , Francia , Humanos , Pruebas de Sensibilidad Microbiana , Saccharomycetales/efectos de los fármacos
16.
Parasitol Res ; 118(11): 3191-3194, 2019 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-31511977

RESUMEN

Aeromonas hydrophila, considered as an emerging pathogen, is increasingly involved in opportunistic human infections. This bacterium, mainly present in aquatic environments, can therefore develop relationships with the free-living amoeba Vermamoeba vermiformis in hospital water networks. We showed in this study that the joint presence of V. vermiformis and A. hydrophila led to an increased bacterial growth in the first 48 h of contact and moreover to the protection of the bacteria in adverse conditions even after 28 days. These results highlight the fact that strategies should be implemented to control the development of FLA in hospital water systems.


Asunto(s)
Aeromonas hydrophila/crecimiento & desarrollo , Amoeba/microbiología , Antibiosis/fisiología , Lobosea/microbiología , Hospitales/estadística & datos numéricos , Humanos , Agua/análisis , Microbiología del Agua
17.
Artículo en Inglés | MEDLINE | ID: mdl-31138564

RESUMEN

The incidence of pulmonary mucormycosis is constantly increasing, especially in hematological patients staying in high-efficiency particulate air-filtered rooms. Pulmonary inhalation of spores may occur outside the hospital, leading to invasive disease once patients received chemotherapies. We developed a new pulmonary mucormycosis mouse model mimicking the expected pathophysiology in human to study antifungal drugs. Naive mice were inoculated intratracheally with Lichtheimia corymbifera spores. After 3 days, mice received corticosteroids and cyclophosphamide and secondarily developed the disease, while only 5% of the initial inoculum was present in the lungs at day 3. Lung colonization with L. corymbifera spores in immunocompetent mice can last at least 44 days. Antifungal drug was administered the day of immunosuppression. Injection of a single 15 mg/kg of body weight dose of liposomal amphotericin B significantly improved survival and pulmonary fungal burden compared with controls, whereas 80 mg/kg oral posaconazole did not. These results show that a unique dose of liposomal amphotericin B offers a real potential decolonization treatment to prevent infection in our mouse model of L. corymbifera lung colonization followed by lung infection.


Asunto(s)
Anfotericina B/uso terapéutico , Antifúngicos/uso terapéutico , Mucormicosis/tratamiento farmacológico , Infecciones del Sistema Respiratorio/tratamiento farmacológico , Animales , Modelos Animales de Enfermedad , Masculino , Ratones , Ratones Endogámicos BALB C , Mucormicosis/microbiología , Infecciones del Sistema Respiratorio/microbiología
18.
J Infect ; 77(6): 463-468, 2018 12.
Artículo en Inglés | MEDLINE | ID: mdl-30417827

RESUMEN

OBJECTIVES: Latent infections are well-known for bacteria such as Mycobacterium tuberculosis and for viruses such as Herpesviridae and parasites like Leishmania spp. or Toxoplasma gondii. However, invasive fungi may also be latent and come to reactivate. The aim of this review is to clarify the reactivation concept in major fungal invasive diseases. METHOD: We have searched for PUBMED publications from 1980 to 2017 with the keywords "fungi", "reactivation", "latency", "dormancy", "granuloma", "Aspergillus", "Mucorales", "Dimorphic fungi", "Histoplasma", "Cryptococcus", "Pneumocystis", "Yeast", "Candida" and "Mold". RESULTS: After primary infection and immune control of the fungus, reactivation can occur following a period of latency. Two conditions must be present: dormancy/survival of the fungi and immunosuppression of the host. Fungal reactivation is easily demonstrated for dimorphic fungi when patients travelling in endemic areas are no longer exposed to fungi at the time they when develop the disease. For cosmopolitan fungi, such as Cryptococcus neoformans, Aspergillus or some emerging fungi, clinical data and animal models have brought some evidence of reactivation. Survival inside macrophages and granuloma formation appear to be predominant conditions to latency. Although granuloma may act as a reservoir for some fungi like Histoplasma or Cryptococcus, its role in mold reactivation has yet to be fully established. CONCLUSIONS: The risk of fungal reactivation should be taken into account in patient management, especially in cases of solid organ transplantation or long-term immunosuppressive treatment.


Asunto(s)
Infecciones Fúngicas Invasoras/patología , Micosis/patología , Animales , Modelos Animales de Enfermedad , Humanos , Terapia de Inmunosupresión/efectos adversos , Infecciones Fúngicas Invasoras/etiología , Ratones , Trasplante de Órganos/efectos adversos
19.
Int J Parasitol ; 48(7): 561-568, 2018 06.
Artículo en Inglés | MEDLINE | ID: mdl-29524527

RESUMEN

The current therapeutic arsenal for toxoplasmosis is restricted to drugs non-specific to the parasite which cause important side effects. Development of more efficient and specific anti-Toxoplasma compounds is urgently needed. Imidazo[1,2-b]pyridazines designed to inhibit the calcium-dependent protein kinase 1 of Toxoplasma gondii (TgCDPK1) and effective against tachyzoite growth in vitro at submicromolar ranges were modified into hydrochloride salts to be administered in vivo in a mouse model of acute toxoplasmosis. All protonated imidazo[1,2-b]pyridazine salts (SP230, SP231 and SP232) maintained their activity on TgCDPK1 and T. gondii tachyzoites. Rat and mouse liver microsomes were used to predict half-life and intrinsic clearance, and the pharmacokinetic profile of the most rapidly degraded imidazo[1,2b]pyridazine salt (SP230) was determined in serum, brain and lungs of mice after a single administration of 50 mg/kg. Compounds were then tested in vivo in a murine model of acute toxoplasmosis. Mice infected with tachyzoites of the ME49 strain of T. gondii were treated for 4, 7 or 8 days with 25 or 50 mg/kg/day of SP230, SP231 or SP232. The parasite burdens were strongly diminished (>90% reduction under some conditions) in the spleen and the lungs of mice treated with imidazo[1,2-b]pyridazine salts compared with untreated mice, without the need for pre-treatment. Moreover, no increases in the levels of hepatic and renal toxicity markers were observed, demonstrating no significant signs of short-term toxicity. To conclude, imidazo[1,2-b]pyridazine salts have strong efficacy in vivo on acute toxoplasmosis and should be further tested in a model of mouse congenital toxoplasmosis.


Asunto(s)
Antiprotozoarios/farmacología , Proteínas Quinasas/metabolismo , Piridazinas/farmacología , Animales , Antiprotozoarios/química , Femenino , Fibroblastos/parasitología , Humanos , Ratones , Estructura Molecular , Proteínas Quinasas/genética , Proteínas Protozoarias/antagonistas & inhibidores , Piridazinas/química
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...